BioSpace News Archive

Vera Therapeutics, Inc. reported its business highlights and financial results for the third quarter ended September 30, 2023.

Recce Pharmaceuticals Ltd today announced it completed dosing the first healthy subjects at the highest concentration of 3,000mg within a fast infusion rate of 15-minutes in a Phase I/II trial evaluating its lead anti-infective candidate, RECCE® 327 (R327).

Recursion, a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced two significant updates with their collaborators NVIDIA and Bayer, and a new collaboration with Tempus Labs as it creates infrastructure and expands its ambitions and scope in the precision oncology space.

PDS Biotechnology Corporation today announced updated survival data from the Phase 2 clinical trial investigating the triple combination of PDS0101, PDS0301 (IL-12 antibody-drug conjugate) and an investigational immune checkpoint inhibitor (ICI) in two groups of advanced cancer patients with various types of human papillomavirus (HPV) 16-positive cancers.

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced its financial results and operational highlights for the third quarter ended September 30, 2023.

Endologix LLC announced today that the company will be presenting in two upcoming healthcare conferences.

Autobahn Therapeutics today announced that Kevin Finney, President and Chief Executive Officer, will present a company overview at the Stifel 2023 Healthcare Conference in New York on Wednesday, November 15, 2023, at 12:40 p.m. ET.

Processa Pharmaceuticals, Inc. announces that Dr. David Young, President of Research and Development, will present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas.

Establishment Labs Holdings Inc. today announced it has received National Medical Products Administration (NMPA) approval in China for Motiva ® Implants.

Artivion, Inc. today announced that it has completed enrollment in the PERSEVERE clinical trial.